AKYLA/ Financials
MarketsScreenerFinancialsResearchChat
Equity / PHARMACEUTICAL PREPARATIONS
Adial Pharmaceuticals, Inc
XNAS · usd
SIC 2834 · PHARMACEUTICAL PREPARATIONS
FIGI BBG00HNGDTS3
3.92▼ 0.30 (-7.11%)
As of 2026-10-23
Price / Volume
Valuation
Market Cap
Enterprise Value
—
Trailing P/E
—
Price / Sales
—
EV / Revenue
—
EV / EBITDA
—
Financial Highlights
Revenue (TTM)
—
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin
—
Net Debt
—
Trading Information
Previous Close
4.22
Day's Range
3.92 – 4.28
52-Week Range
0.13 – 7.20
Volume
47.3K
Avg Volume
37.9K
Share Statistics
Shares Outstanding
Employees
6
Exchange
XNAS
Listed
2018-07-27
Share count as of August 12, 2026

Adial Pharmaceuticals, Inc (ADIL) Financial Statements

View
Income Statement
Detail
Standard
Period
Quarterly
Loading Income Statement…
Key questions about Adial Pharmaceuticals, Inc (ADIL)
What is Adial Pharmaceuticals, Inc's Market Cap?
Adial Pharmaceuticals, Inc's Market Cap is $10.3M, based on as-reported figures from SEC (XBRL) filings.
What is Adial Pharmaceuticals, Inc's Net Income (TTM)?
Adial Pharmaceuticals, Inc's Net Income (TTM) is -$8.1M, based on as-reported figures from SEC (XBRL) filings.
What is Adial Pharmaceuticals, Inc's EBITDA?
Adial Pharmaceuticals, Inc's EBITDA is -$7.9M, based on as-reported figures from SEC (XBRL) filings.
What is Adial Pharmaceuticals, Inc's Diluted EPS (TTM)?
Adial Pharmaceuticals, Inc's Diluted EPS (TTM) is -3.07, based on as-reported figures from SEC (XBRL) filings.
Akyla / Financials · ADILAs-filed SEC (XBRL) data
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022
Operating Expenses:
Research and development expenses—
General and administrative expenses—
Acquired in process research and development———
Total Operating Expenses—
Loss From Operations—
Other Income (Expense)
Interest income—
Change in fair value of milestone warrant rights liability———
Financing Expense Related To Milestone Warrant Rights Liability———
Loss on extinguishment———
Loss on equity method investment—
Other income (expenses)———
Total other income (expense)—
Net Loss
Loss per share, basic——
Loss per share, diluted——